A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

NCT05029895 · clinicaltrials.gov ↗
COMPLETED
Status
167
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie